MedPath

Daunorubicin Advanced Drug Monograph

Published:Jul 21, 2025

Generic Name

Daunorubicin

Brand Names

Cerubidine, Vyxeos, Vyxeos liposomal (previously Vyxeos)

Drug Type

Small Molecule

Chemical Formula

C27H29NO10

CAS Number

20830-81-3

Associated Conditions

Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor

Daunorubicin (DB00694): A Comprehensive Monograph on its Chemistry, Pharmacology, and Clinical Utility

Part I: Executive Summary

Daunorubicin is a foundational antineoplastic agent belonging to the anthracycline class of antibiotics. First isolated from Streptomyces species and approved for medical use in 1979, it has remained a cornerstone of chemotherapy for hematologic malignancies, particularly acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).[1] Its potent cytotoxic activity stems from a multifaceted mechanism of action, primarily involving the intercalation into DNA and the inhibition of topoisomerase II, an enzyme critical for DNA replication and repair. This dual action leads to catastrophic DNA damage and subsequent cancer cell apoptosis.[1]

However, the very mechanism that confers its efficacy is also responsible for its significant and often dose-limiting toxicities. The clinical use of daunorubicin is perpetually constrained by severe myelosuppression and a cumulative, dose-dependent cardiotoxicity that can manifest as potentially fatal congestive heart failure, sometimes months or even years after treatment completion.[3] This therapeutic paradox—where efficacy and toxicity are inextricably linked—has driven decades of clinical and pharmaceutical research aimed at optimizing its therapeutic index.

The clinical evolution of daunorubicin is characterized by two major trends. The first is the data-driven adoption of dose-intensification strategies in AML. Landmark clinical trials have demonstrated that higher doses (e.g., 90 mg/m²) significantly improve survival outcomes in younger, fitter patients compared to historical standard doses, establishing a new standard of care for select populations.[4] The second trend is pharmaceutical innovation in drug delivery systems. The development of liposomal formulations, such as DaunoXome for Kaposi's sarcoma and, most notably, the co-formulated daunorubicin-cytarabine liposome (Vyxeos) for high-risk AML, represents a sophisticated effort to alter the drug's pharmacokinetics, enhance therapeutic targeting, and mitigate systemic toxicity, leading to proven survival benefits.[2] This monograph provides an exhaustive analysis of daunorubicin, synthesizing its fundamental chemistry, complex pharmacology, clinical applications, and evolving role in modern oncology.

Part II: Chemical Identity and Physicochemical Properties

A precise understanding of daunorubicin's chemical and physical characteristics is fundamental to its formulation, stability, handling, and biological activity.

Chemical Identifiers

Daunorubicin is a small molecule that exists as a base and, more commonly in pharmaceutical preparations, as a hydrochloride salt. This distinction is critical for accurate identification and documentation. The primary identifiers are consolidated in Table 1.

Table 1: Summary of Daunorubicin Identifiers and Physicochemical Properties

PropertyValueSource(s)
Drug NameDaunorubicin1
SynonymsDaunomycin, Rubidomycin, DNR7
Systematic (IUPAC) Name(8S,10S)-8-Acetyl-10-oxy-6,8,11-trihydroxy-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione1
Chemical FormulaC27​H29​NO10​1
Molecular Weight (Base)527.52 g/mol1
Molecular Weight (HCl Salt)564.0 g/mol9
CAS Number (Base)20830-81-31
CAS Number (HCl Salt)23541-50-69
DrugBank IDDB006941
PubChem CID303231
Physical DescriptionThin, red needles; Light-red to brown solid10
Melting Point208-209 °C10
Boiling Point190 °C (decomposes)10
Water Solubility30,000 mg/L at 25 °C10
StabilityUnstable in solutions with pH>8. Reconstituted solution stable for 24h at room temp, 48h refrigerated. Must be protected from sunlight.10

Physicochemical and Experimental Properties

Daunorubicin presents as a distinctive reddish, crystalline solid.[10] This color is a direct result of its chromophoric tetracyclic quinone structure and is clinically significant, as it imparts a noticeable red-orange color to the urine of patients for 1-2 days following administration, a harmless effect that requires patient counseling to avoid alarm.[12]

The drug is soluble in water and methyl alcohol but insoluble in less polar organic solvents like chloroform and benzene.[10] Its stability is highly pH-dependent. In solutions with a pH greater than 8, daunorubicin hydrochloride is unstable and undergoes decomposition, which is visibly indicated by a color change from red to a blue-purple hue.[10] This chemical property dictates strict clinical handling protocols. Pharmaceutical preparations must be reconstituted and diluted in solutions that are neutral to slightly acidic, such as 5% Dextrose Injection or 0.9% Sodium Chloride Injection, to ensure drug integrity.[12] Co-administration with alkaline drugs in the same intravenous line is contraindicated. Furthermore, reconstituted solutions must be protected from direct sunlight to prevent photodegradation.[10] Liposomal formulations, such as DaunoXome, lack preservatives and demand strict aseptic technique during preparation and handling to prevent microbial contamination.[10]

Part III: Comprehensive Pharmacological Profile

The pharmacological profile of daunorubicin is defined by its potent, multi-pronged cytotoxic mechanism, its cell cycle-nonspecific activity, and its complex pharmacokinetic behavior, which includes extensive metabolism into a biologically active metabolite.

Section 3.1: Classification and Mechanism of Action

Daunorubicin is classified as an anthracycline antibiotic, an aminoglycoside, and a topoisomerase II inhibitor.[2] Originally isolated from

Streptomyces peucetius, its antineoplastic effects are not attributed to a single molecular interaction but rather to a combination of cytotoxic activities that ultimately overwhelm the cell's ability to survive and replicate.[1]

The principal mechanisms include:

  1. DNA Intercalation: The planar, polycyclic aromatic core of the daunorubicin molecule inserts itself between the base pairs of the DNA double helix.[1] This process, known as intercalation, has a high preference for sequences of two adjacent guanine-cytosine (G/C) base pairs.[1] The physical insertion of the drug distorts the helical structure of DNA, causing localized unwinding and creating a steric blockade. This physical impediment obstructs the progression of DNA and RNA polymerases along the DNA template, thereby inhibiting both DNA replication and transcription.[1]
  2. Topoisomerase II Inhibition: This is widely considered the most critical mechanism for its anticancer activity.[1] Topoisomerase II is an essential enzyme that manages DNA topology by creating transient double-strand breaks to relieve supercoiling during replication. Daunorubicin interferes with this process by stabilizing the "cleavable complex," a covalent intermediate formed between topoisomerase II and the cleaved DNA strands.[1] By preventing the enzyme from completing its catalytic cycle and resealing the break, daunorubicin converts a transient, necessary enzymatic step into a permanent, lethal DNA double-strand break. The accumulation of these breaks triggers cellular DNA damage response pathways, ultimately leading to programmed cell death (apoptosis).[1]
  3. Generation of Reactive Oxygen Species (ROS): The quinone moiety within the anthracycline structure can undergo enzymatic reduction to a semiquinone free radical. In the presence of oxygen, this radical can be re-oxidized back to the parent quinone, generating superoxide radicals in the process. This redox cycling produces a cascade of ROS, including hydrogen peroxide and hydroxyl radicals, which inflict widespread oxidative damage to DNA, cellular proteins, and lipid membranes, contributing to both its cytotoxic and cardiotoxic effects.[2]

A crucial aspect of daunorubicin's pharmacology is that its mechanism of action is inextricably linked to its primary dose-limiting toxicity. The inhibition of topoisomerase II is essential for killing cancer cells, which primarily express the topoisomerase II-alpha isoform.[17] However, this same mechanism is responsible for damaging heart muscle cells. Cardiomyocytes express the topoisomerase II-beta isoform, and the formation of daunorubicin-stabilized cleavable complexes with this enzyme leads to mitochondrial dysfunction and myocardial cell death.[2] This demonstrates that the severe cardiotoxicity is not an off-target effect but an on-target effect in the wrong tissue, which explains the profound difficulty in separating the drug's therapeutic benefits from its cardiac risks.

Section 3.2: Pharmacodynamics

The primary pharmacodynamic effect of daunorubicin is its profound cytotoxicity, which results in the slowing or cessation of cancer cell proliferation.[1] This activity is characterized as cell cycle phase-nonspecific, meaning the drug is capable of killing cells at all stages of the cell cycle, including resting cells in G0.[15] This property makes it particularly effective against rapidly dividing cell populations, such as those found in acute leukemias.

Section 3.3: Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion - ADME)

The disposition of daunorubicin in the body is complex and characterized by intravenous-only administration, wide tissue distribution, extensive metabolism to an active compound, and a prolonged elimination phase.

  • Absorption: Daunorubicin has no oral bioavailability and must be administered intravenously.[1]
  • Distribution: Following intravenous injection, the drug is rapidly and widely distributed into tissues, achieving the highest concentrations in the liver, kidneys, lungs, spleen, and heart.[15] This extensive tissue binding contributes to its large volume of distribution. It does not effectively penetrate the blood-brain barrier, limiting its efficacy against central nervous system malignancies, but it is known to cross the placental barrier, posing a risk to a developing fetus.[15] Plasma protein binding is moderate, at approximately 63%.[15]
  • Metabolism: Daunorubicin is rapidly and extensively metabolized, principally in the liver but also in other tissues, by cytoplasmic aldo-keto reductases.[1] The primary metabolic pathway is the reduction of the side-chain ketone to an alcohol, forming the major active metabolite, daunorubicinol.[15] Daunorubicinol retains significant cytotoxic activity and contributes to both the therapeutic and toxic effects of the drug. There is wide inter-individual variability in the pharmacokinetics of daunorubicin, which has been linked to genetic polymorphisms in metabolizing enzymes like carbonyl reductase 1 (CBR1) and drug efflux transporters like ABCB1.[19] Studies have shown that certain genetic variants can lead to higher plasma drug exposure (Area Under the Curve, AUC), which may correlate with treatment response and toxicity.[20]
  • Excretion: Elimination of daunorubicin and its metabolites is triphasic. The primary route of excretion is via hepatobiliary secretion into the bile, accounting for approximately 40% of the dose being eliminated in the feces.[18] Renal excretion accounts for about 25% of the dose over five days, with the drug eliminated as both unchanged daunorubicin and the active daunorubicinol.[1]

The pharmacokinetic profile is defined by the long half-lives of both the parent drug and its active metabolite, as detailed in Table 2.

Table 2: Key Pharmacokinetic Parameters of Daunorubicin and Daunorubicinol

ParameterDaunorubicin (Parent Drug)Daunorubicinol (Active Metabolite)Clinical ImplicationSource(s)
Terminal Half-life~18.5 hours~26.7 hoursThe metabolite's longer half-life leads to prolonged exposure to a cytotoxic agent, driving delayed toxicities like myelosuppression.1
Primary Route of EliminationHepatobiliary (40% in feces)HepatobiliaryDose reduction is mandatory in patients with hepatic impairment to prevent excessive toxicity.17
Renal Excretion~25% (as active drug/metabolite)~25% (as active drug/metabolite)Dose reduction is required in severe renal impairment.17
Biological ActivityActiveActiveBoth the parent drug and the metabolite contribute to the overall therapeutic effect and toxicity profile.15

The extended half-life of daunorubicinol is of major clinical importance. It means that the body remains exposed to a potent cytotoxic compound for a significant period after the initial infusion has ended. This sustained action is a key driver of the delayed onset of major toxicities, particularly myelosuppression, where the nadir (lowest point) of blood cell counts typically occurs one to two weeks after drug administration. This pharmacokinetic reality dictates the schedule of chemotherapy cycles and the necessary monitoring period for adverse effects.

Part IV: Clinical Applications and Therapeutic Efficacy

Daunorubicin is a cornerstone agent in the treatment of several hematologic malignancies, with its efficacy established over decades of clinical use. Its therapeutic role has evolved with the advent of dose-intensification strategies and novel formulations.

Section 4.1: FDA-Approved and Off-Label Indications

FDA-Approved Indications:

  • Acute Myeloid Leukemia (AML) / Acute Nonlymphocytic Leukemia (ANLL): Daunorubicin is a standard-of-care component for remission induction therapy in adults with AML, including its myelogenous, monocytic, and erythroid subtypes. It is almost always used in combination with other cytotoxic agents, most commonly cytarabine in the "7+3" regimen.[1]
  • Acute Lymphoblastic Leukemia (ALL): The drug is approved for remission induction in both pediatric and adult ALL, where it is integrated into multi-agent chemotherapy protocols, such as those including vincristine and prednisone.[1]

Off-Label and Other Established Uses:

  • Chronic Myelogenous Leukemia (CML): Daunorubicin is used in combination regimens to treat the blastic phase of CML, an aggressive transformation of the disease that resembles acute leukemia.[1]
  • Kaposi's Sarcoma (KS): The conventional formulation of daunorubicin is indicated for KS.[1] A specific liposomal formulation, DaunoXome, is approved as a first-line therapy for advanced HIV-associated Kaposi's sarcoma.[2]
  • Other Hematologic Cancers: Daunorubicin is a component of aggressive regimens like CHOP (cyclophosphamide, doxorubicin/daunorubicin, vincristine, prednisone) for treating adult T-cell leukemia/lymphoma and has been used for neuroblastoma and pediatric anaplastic large cell lymphoma.[1]

An attempt to use daunorubicin for an ophthalmic purpose—intravitreal injection to prevent proliferative vitreoretinopathy after retinal detachment surgery—was investigated but proved ineffective and is not a current use.[1]

Section 4.2: Clinical Efficacy and Treatment Outcomes

The efficacy of daunorubicin is well-documented, particularly in the context of combination chemotherapy for acute leukemias.

  • Efficacy in AML: When used as a single agent for adult ANLL, daunorubicin can induce complete remission (CR) in 40-50% of patients. However, its efficacy is dramatically improved in combination therapy. The standard "7+3" regimen, combining daunorubicin with a 7-day continuous infusion of cytarabine, boosts the CR rate to a range of 53-65%.[2]
  • The Impact of Dose Intensification in AML: A pivotal shift in AML treatment has been the validation of high-dose daunorubicin. Clinical evidence strongly supports that for younger patients (generally <65 years) with good performance status, increasing the daunorubicin dose from the standard 45 mg/m² to 90 mg/m² for three days (a cumulative induction dose of 270 mg/m²) leads to higher CR rates and, more importantly, improved overall survival.[4] This benefit is particularly pronounced in patients with favorable or intermediate-risk cytogenetics and those with specific molecular mutations like NPM1 or FLT3-ITD.[4] This data-driven evolution has redefined the standard of care, though this dose-intensified approach is not recommended for older patients, in whom it does not improve survival and increases toxicity.[4]
  • Efficacy in ALL: In pediatric ALL, the addition of daunorubicin to a backbone of vincristine and prednisone has been shown to prolong the duration of complete remission.[2] In adult ALL, incorporating daunorubicin into a triple-therapy regimen with vincristine, prednisone, and L-asparaginase dramatically increased the CR rate from 47% to 83%.[2]
  • Efficacy of Liposomal Formulations (Vyxeos): The approval of Vyxeos (liposomal daunorubicin and cytarabine) marked a significant advance for patients with high-risk AML, specifically therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). The rationale behind this formulation is to deliver the two drugs together at a fixed synergistic 1:5 molar ratio, maintaining this optimal ratio for a longer duration in the bone marrow compared to conventional co-administration. In its pivotal phase III clinical trial, Vyxeos demonstrated a statistically significant and clinically meaningful improvement in overall survival, with a median OS of 9.6 months compared to just 5.9 months for the conventional 7+3 control arm.[6] This result validated the sophisticated pharmacological concept of leveraging pharmacokinetics through formulation to achieve superior outcomes in a patient population with a historically poor prognosis.

Part V: Dosage, Administration, and Pharmaceutical Formulations

The clinical use of daunorubicin requires strict adherence to established protocols for dosing, administration, and management of its various pharmaceutical forms to maximize efficacy while minimizing life-threatening toxicities.

Section 5.1: Dosing Regimens and Lifetime Cumulative Dose Limits

Dosing is typically calculated based on body surface area (m2) and varies by indication, patient age, and combination regimen.

  • Dosing in AML (Adults, in combination with cytarabine):
  • Standard Dose: For patients <60 years old, a common regimen is 45 mg/m² administered intravenously (IV) daily for 3 days. For patients >60 years old, the dose is often reduced to 30 mg/m² IV daily for 3 days.[25]
  • High-Dose (Dose Intensification): For younger, fit patients (<65 years), the recommended dose is 90 mg/m² IV daily for 3 days.[4]
  • Dosing in ALL (Adults): A typical dose is 45 mg/m² IV daily on days 1, 2, and 3 as part of a multi-agent protocol.[25]
  • Pediatric Dosing: Dosing in children is often stratified by age and size. For children younger than 2 years or with a body surface area (BSA) less than 0.5 m², dosing may be based on body weight (e.g., 1 mg/kg). For older children, dosing is based on BSA (e.g., 25 mg/m² weekly).[12]

Lifetime Cumulative Dose Limits:

To mitigate the risk of irreversible, delayed-onset cardiotoxicity, there are strict lifetime maximum cumulative doses that must not be exceeded. These limits include all anthracyclines received by the patient (e.g., doxorubicin, idarubicin).

  • Adults: The lifetime limit is 550 mg/m². This is reduced to 400 mg/m² for patients who have received prior radiation therapy to the mediastinal (chest) area.[2]
  • Children (>2 years): The lifetime limit is 300 mg/m².[3]
  • Children (<2 years): The lifetime limit is 10 mg/kg.[3]

Section 5.2: Dose Adjustments for Organ Impairment

Daunorubicin's clearance is dependent on both hepatic and renal function, necessitating dose adjustments in patients with organ impairment to prevent excessive toxicity.

  • Hepatic Impairment:
  • Serum Bilirubin 1.2 to 3.0 mg/dL: Administer 75% of the standard dose.[22]
  • Serum Bilirubin > 3.0 mg/dL: Administer 50% of the standard dose.[22]
  • Renal Impairment:
  • Serum Creatinine > 3.0 mg/dL: Administer 50% of the standard dose.[22]

Section 5.3: Administration, Handling, and Extravasation Management

  • Route of Administration: Daunorubicin is for intravenous use only. It must never be administered via the intramuscular or subcutaneous routes, as this will cause severe tissue damage.[1]
  • IV Administration Technique: It is typically administered as a rapid intravenous infusion or as a slow IV push over 3 to 10 minutes. It should be injected into the side port or tubing of a freely flowing IV infusion of a compatible solution (5% Dextrose or 0.9% Sodium Chloride) to ensure rapid dilution and minimize vein irritation.[1] A facial flush during administration can be a sign that the infusion rate is too rapid.[12]
  • Extravasation Management: Daunorubicin is a potent vesicant, meaning it can cause severe tissue damage and necrosis if it leaks outside of the vein (extravasation).[1] If a patient reports pain, stinging, or burning, or if swelling or redness is observed at the IV site, the infusion must be stopped immediately. Management involves attempting to aspirate any residual drug from the catheter and applying cold packs to the area. The site must be monitored closely for signs of tissue breakdown.[13]

Section 5.4: Pharmaceutical Formulations

It is critically important to distinguish between the different formulations of daunorubicin, as they have different indications, dosing, and safety profiles. They are not interchangeable.

Table 3: Comparison of Daunorubicin Formulations

FormulationActive Ingredient(s)Approved Indication(s)Key Pharmacokinetic DifferenceCritical Administration NotesSource(s)
Cerubidine® (Conventional)Daunorubicin HClAML, ALLStandard pharmacokinetic profile.The baseline formulation for most standard and high-dose regimens.3
DaunoXome® (Liposomal)Daunorubicin CitrateAdvanced HIV-associated Kaposi's SarcomaEncapsulation in liposomes alters tissue distribution, leading to accumulation in KS lesions.Dosed differently from conventional form.2
Vyxeos® (Liposomal)Daunorubicin and CytarabineHigh-risk AML (t-AML, AML-MRC)Co-encapsulation maintains a fixed 1:5 molar ratio of the two drugs, enhancing synergistic delivery to the bone marrow.FDA Black Box Warning: DO NOT INTERCHANGE with other daunorubicin- or cytarabine-containing products.2

The existence of these three distinct formulations underscores that the delivery vehicle can be as important as the active drug itself. The FDA's stark "DO NOT INTERCHANGE" warning for Vyxeos is a direct response to the high risk of fatal medication errors if it were to be confused with conventional daunorubicin or cytarabine. Vyxeos is not merely a different brand; it is a fundamentally different drug product with a unique composition, indication, and dosing regimen, and must be treated as such to ensure patient safety.

Part VI: Safety Profile and Toxicology

The clinical utility of daunorubicin is defined and limited by its profound toxicity profile. Safe administration requires a deep understanding of its adverse effects, contraindications, and the necessary precautions to mitigate risk.

Section 6.1: FDA Black Box Warnings

The U.S. Food and Drug Administration (FDA) has mandated several black box warnings for daunorubicin, highlighting its most severe and life-threatening risks [3]:

  1. Myocardial Toxicity: Daunorubicin can cause dose-dependent and potentially fatal congestive heart failure (CHF). This cardiotoxicity can be acute but is more feared for its delayed onset, occurring months to years after therapy completion. The risk increases significantly as the lifetime cumulative dose rises.
  2. Severe Myelosuppression: At therapeutic doses, daunorubicin is a potent bone marrow suppressant. This effect is expected in all patients and leads to severe neutropenia, thrombocytopenia, and anemia, placing the patient at high risk for life-threatening infections or hemorrhage.
  3. Extravasation Risk: The drug must only be given via a rapidly flowing intravenous infusion. It is a powerful vesicant, and if extravasation occurs, it will cause severe local tissue necrosis. Intramuscular or subcutaneous administration is strictly contraindicated.
  4. Administration by Experienced Physicians: Due to its complex toxicity profile and the need for intensive supportive care, it is recommended that daunorubicin only be administered by physicians experienced in leukemia chemotherapy and in facilities equipped to manage severe complications like overwhelming infection or hemorrhage.

Section 6.2: Comprehensive Adverse Effects Profile

The adverse effects of daunorubicin are numerous and affect multiple organ systems.

  • Very Common (>10% incidence):
  • Hematologic: Myelosuppression is the dose-limiting toxicity and is observed in virtually all patients. This manifests as severe neutropenia (low white blood cells), thrombocytopenia (low platelets), and anemia (low red blood cells).[1]
  • Gastrointestinal: Nausea and vomiting are very common, affecting up to 85% of patients in some studies.[15] Mucositis (inflammation and ulceration of the mouth and throat), diarrhea, and loss of appetite are also frequent.[1]
  • Dermatologic: Complete and reversible alopecia (hair loss) is a common and expected side effect.[1]
  • Cardiovascular:
  • Acute Toxicity: Occurring soon after administration and generally not dose-related, these effects include transient, non-specific ST-T wave changes on an electrocardiogram (ECG), QT prolongation, and arrhythmias. Rare cases of acute pericarditis-myocarditis have been reported.[12]
  • Delayed/Chronic Toxicity: This is the most feared cardiac effect. It is a cumulative dose-related, progressive, and often irreversible cardiomyopathy characterized by damage to and loss of cardiac myocytes. This leads to left ventricular dysfunction and can culminate in CHF months to years after treatment has ended.[12] The "long shadow" of this late effect necessitates lifelong surveillance for cancer survivors, especially those treated in childhood, as it creates a permanent risk that can impact future health and lifestyle.[14]
  • Other Significant Effects:
  • Urine Discoloration: A harmless but notable side effect is the red-orange discoloration of urine for 1-2 days after a dose, due to the drug's color.[12]
  • Tumor Lysis Syndrome (TLS): The rapid destruction of a large burden of cancer cells can release massive amounts of intracellular contents (potassium, phosphate, uric acid) into the bloodstream. The resulting hyperuricemia can lead to acute kidney injury or gout. Prophylaxis with hydration and uric acid-lowering agents like allopurinol is often necessary.[15]
  • Secondary Malignancies: As a DNA-damaging agent, daunorubicin carries a small but real risk of causing secondary cancers, such as therapy-related AML or myelodysplastic syndrome, years after treatment.[3]
  • Radiation Recall: Daunorubicin can reactivate tissue injury in areas previously treated with radiation therapy, causing inflammation and skin reactions weeks to months after radiation was completed.[15]

Section 6.3: Management of Key Toxicities

  • Cardiotoxicity: Proactive monitoring is essential. This includes a baseline assessment of cardiac function (e.g., echocardiogram to measure left ventricular ejection fraction, or LVEF) and serial monitoring during and after therapy.[3] For patients at high risk, the cardioprotective agent Dexrazoxane can be considered. Dexrazoxane is thought to work by chelating iron to reduce ROS formation and by inhibiting the topoisomerase II-beta isoform found in cardiomyocytes, thereby preventing daunorubicin from causing DNA damage in the heart without compromising its antitumor efficacy.[2]
  • Myelosuppression: Requires frequent monitoring of complete blood counts. Patients must be meticulously educated on the signs and symptoms of infection (e.g., fever, chills, sore throat) and bleeding (e.g., unusual bruising, petechiae, black stools) and instructed to seek immediate medical care if they occur.[12] Prophylactic antibiotics and growth factors (e.g., G-CSF) may be used in some settings.

Section 6.4: Contraindications, Precautions, and Interactions

  • Contraindications: The only absolute contraindication is a known hypersensitivity to daunorubicin or any of its components.[2]
  • Precautions:
  • Extreme caution is warranted in patients with pre-existing heart disease, as their risk of cardiotoxicity is significantly elevated.[3]
  • Patients with severe hepatic or renal impairment require dose reductions.[25]
  • Daunorubicin should not be initiated in patients with active, uncontrolled infections.[29]
  • Pregnancy and Fertility: Daunorubicin is classified as Pregnancy Category D. It is teratogenic, fetotoxic, and can cause abortions.[1] Women of childbearing potential must avoid pregnancy. Both male and female patients should use effective contraception during and for at least 6 months after treatment. The drug can cause irreversible infertility.[15]
  • Drug-Drug Interactions: Daunorubicin has over 500 documented drug interactions.[30] Clinically significant interactions include:
  • P-glycoprotein (MDR1) and BCRP Transporter Interactions: Daunorubicin is a substrate for these efflux pumps. Inhibitors of these transporters (e.g., clarithromycin, cyclosporine, amiodarone) can increase daunorubicin plasma concentrations and toxicity. Inducers (e.g., apalutamide, St. John's Wort) can decrease its concentration and efficacy.[25]
  • Additive Toxicities: Co-administration with other cardiotoxic agents (e.g., doxorubicin, trastuzumab, cyclophosphamide) or other myelosuppressive agents will increase the risk and severity of these respective toxicities.[2]
  • Live Vaccines: Administration of live vaccines (e.g., MMR, varicella) is contraindicated in immunosuppressed patients receiving daunorubicin due to the risk of disseminated, life-threatening infections.[25]
  • Drug-Food Interactions: There are no specific, clinically significant drug-food interactions documented for daunorubicin.[30] General dietary advice focuses on managing gastrointestinal side effects, such as eating small, frequent meals to combat nausea and maintaining adequate hydration to help prevent kidney issues from tumor lysis syndrome.[26]

Part VII: Comparative Analysis with Other Anthracyclines

To fully understand daunorubicin's place in therapy, it is useful to compare it with other members of the anthracycline class, particularly its close structural analog doxorubicin and its common therapeutic alternative in AML, idarubicin.

Section 7.1: Daunorubicin vs. Doxorubicin

  • Structural and Synthetic Relationship: Doxorubicin and daunorubicin are nearly identical, differing only by a single hydroxyl group on the C-14 position of the aglycone ring.[34] Daunorubicin actually serves as the chemical starting material for the semi-synthetic production of doxorubicin.[1]
  • Clinical Spectrum of Activity: This minor structural modification results in a major divergence in clinical utility. Daunorubicin's use is almost entirely confined to hematologic malignancies like leukemias.[32] In contrast, doxorubicin possesses one of the broadest spectrums of activity of any anticancer drug, demonstrating efficacy against numerous solid tumors (e.g., breast, bladder, lung, ovarian cancers) as well as lymphomas and leukemias.[32]
  • Efficacy in Leukemia: In the context of acute leukemia where both can be used, their efficacy appears comparable. A randomized trial in children with newly diagnosed ALL found that a single dose of doxorubicin (30 mg/m²) produced a similar degree of leukemic cell reduction in the peripheral blood as daunorubicin at both 30 mg/m² and 40 mg/m² doses.[38]
  • Comparative Toxicity: Both agents share the hallmark anthracycline toxicities of myelosuppression and cardiotoxicity.[32] Anecdotally and in some studies, daunorubicin is reported to cause a higher incidence of nausea and vomiting than doxorubicin.[15] The most significant point of debate is their relative cardiotoxicity. For many years, the dose equivalence ratio for cardiotoxicity was assumed to be 1:1, based on their similar hematologic toxicity.[39] However, this assumption has been challenged by a large, retrospective analysis of over 15,000 childhood cancer survivors. This study modeled the dose-response relationship for late-onset heart failure and found that daunorubicin was substantially less cardiotoxic, with a dose equivalence ratio of approximately 0.5:1 relative to doxorubicin.[39] This suggests that a 100 mg/m² cumulative dose of daunorubicin carries a similar long-term cardiac risk as a 50 mg/m² cumulative dose of doxorubicin. If this finding is validated, it could have practice-changing implications, potentially allowing for safer or more intensive daunorubicin-based regimens and altering long-term cardiac surveillance guidelines for survivors.

Section 7.2: Daunorubicin vs. Idarubicin

This comparison is highly relevant for the induction treatment of AML.

  • Efficacy: The question of which agent is superior for AML induction remains a subject of debate, with clinical trial data presenting a nuanced picture. A meta-analysis suggested that idarubicin (12 mg/m²) yielded a significantly higher CR rate after the first induction cycle compared to high-dose daunorubicin (HDD, defined as >60 mg/m²), although this did not translate into a long-term overall survival benefit.[40] In contrast, a large randomized controlled trial by the Japan Adult Leukemia Study Group found that high-dose daunorubicin (50 mg/m² for 5 days) was equally effective as standard-dose idarubicin (12 mg/m² for 3 days), with no difference in CR rates or 5-year overall survival.[41] Further complicating the picture, other studies suggest that the optimal choice may depend on the patient's molecular profile; for instance, one trial indicated that high-dose daunorubicin (90 mg/m²) might provide a superior survival benefit over idarubicin specifically in patients with FLT3-mutated AML.[42] This body of evidence suggests that there is likely no single "winner" for the general AML population. The choice may depend on the specific treatment goals and, increasingly, the patient's cytogenetic and molecular risk factors.
  • Toxicity: The meta-analysis comparing idarubicin and HDD found no significant differences in the rates of induction-related mortality, febrile neutropenia, or cardiotoxicity between the two agents.[40]

Table 4: Comparative Summary of Anthracyclines for Leukemia Induction

AgentPrimary Clinical SpectrumEfficacy in AML (vs. other anthracyclines)Relative Cardiotoxicity (vs. Doxorubicin)Key Non-Cardiac ToxicitiesSource(s)
Daunorubicin (Standard Dose)Hematologic MalignanciesInferior to high-dose daunorubicin and idarubicin in some studies.Potentially lower (~0.5:1)High rates of Nausea/Vomiting32
Daunorubicin (High Dose)Hematologic MalignanciesComparable to idarubicin overall; may be superior in FLT3-mutated AML.Potentially lower (~0.5:1)Myelosuppression, Mucositis41
DoxorubicinBroad (Solid Tumors & Hematologic)Used in some leukemia regimens; efficacy comparable to daunorubicin.Baseline (1:1)Myelosuppression, Mucositis32
IdarubicinHematologic MalignanciesHigher initial CR rate vs. HDD in some analyses; long-term OS comparable.Not well-defined vs. DoxorubicinMyelosuppression, Mucositis40

Part VIII: Regulatory and Commercial History

The trajectory of daunorubicin from a natural product discovery to a modern, reformulated chemotherapeutic agent illustrates the classic lifecycle of a pharmaceutical product.

Section 8.1: Discovery and FDA Approval Timeline

  • Discovery: Daunorubicin was co-discovered in the early 1960s by two independent research groups: one at Farmitalia Research Laboratories in Italy and another in France. It was isolated from a red-pigmented strain of the soil bacterium Streptomyces peucetius.[1] The name is a portmanteau reflecting its dual origins: "Dauni," a pre-Roman tribe from the Italian region of its discovery, and "rubis," the French word for ruby, describing its vibrant color.[1]
  • Initial FDA Approval: Following successful clinical trials in the 1960s, conventional daunorubicin was first approved for medical use in the United States in 1979.[1] Its primary brand name, Cerubidine, was listed as approved prior to January 1, 1982.[43]
  • Liposomal Formulation Approvals:
  • DaunoXome (daunorubicin citrate liposome): This formulation received Orphan Drug designation for HIV-associated Kaposi's sarcoma in 1993 and was granted marketing approval on April 8, 1996.[23]
  • Vyxeos (daunorubicin and cytarabine liposome): Representing a major modern advance, Vyxeos was approved on August 3, 2017, for adults with newly diagnosed, high-risk forms of AML (t-AML or AML-MRC). Its development and review were expedited through FDA's Breakthrough Therapy and Orphan Drug designation programs.[6] The indication was expanded to include pediatric patients aged one year and older in March 2021.[28]

Section 8.2: Brand Names and Patent Status

  • Brand Names: In the United States, the most recognized brand name for conventional daunorubicin is Cerubidine.[3] Internationally, it is marketed under a multitude of names, including Daunoblastin, Daunocin, and Rubomycin.[45] The liposomal formulations are marketed as DaunoXome and Vyxeos.[23]
  • Patent History and Generic Competition: The original composition of matter patents protecting daunorubicin expired in the 1990s.[43] This patent cliff opened the market to generic manufacturers, leading to increased price competition and a significant decline in revenue for the branded product, with one analysis noting a 17% drop from peak sales figures.[43] Today, the conventional form is widely available as a generic. The modern patent landscape is focused on protecting advanced delivery systems. Vyxeos, for example, is protected by a portfolio of patents covering its specific liposomal composition, fixed drug ratio, and manufacturing methods, with patent exclusivity expected to last into the 2030s.[46] This demonstrates a common pharmaceutical lifecycle extension strategy, where innovation in formulation and delivery technology for an old, off-patent molecule creates a new, valuable, and patent-protected therapeutic product. The rapid approval of Vyxeos, facilitated by regulatory incentives for drugs that address serious unmet needs, underscores how these pathways can successfully stimulate innovation for patient populations with poor-prognosis diseases.[6]

Part IX: Conclusion and Expert Recommendations

Daunorubicin is a potent and indispensable cytotoxic agent that has been integral to remission induction therapy for acute leukemias for over four decades. Its clinical utility, however, is perpetually defined by the narrow therapeutic window between its profound efficacy and its severe, predictable toxicities, primarily irreversible cardiotoxicity and life-threatening myelosuppression. The history of its clinical use is a testament to the persistent efforts of clinicians and pharmaceutical scientists to optimize this balance. This evolution has progressed from establishing standard-dose regimens to the data-driven adoption of dose intensification for improved survival, and most recently, to the design of sophisticated liposomal formulations that leverage pharmacokinetics to enhance the therapeutic index.

Based on this comprehensive analysis, the following recommendations are put forth for clinical practice and future research:

Expert Recommendations for Clinical Practice:

  1. Prioritize Individualized Patient Selection: The decision to use daunorubicin, and at what intensity, must be tailored to the individual patient. High-dose therapy (90 mg/m²) should be the strong consideration for younger (<65 years) and medically fit AML patients, especially those with favorable molecular markers (NPM1, FLT3-ITD), where the survival benefit is most clearly established. For older or less fit patients, or those with adverse-risk disease, standard-dose daunorubicin or alternative regimens should be prioritized to avoid excessive toxicity without a clear survival advantage.
  2. Maintain Vigilant Toxicity Monitoring: Given the profound risks, rigorous monitoring is non-negotiable. This must include a baseline and serial assessment of cardiac function (LVEF via echocardiogram or MUGA scan), frequent monitoring of complete blood counts through the nadir and recovery, and diligent assessment of hepatic and renal function with strict adherence to dose adjustment guidelines.
  3. Implement Comprehensive Survivorship Care: For patients who achieve long-term remission, particularly those treated in childhood, the lifelong risk of delayed-onset cardiotoxicity must be addressed. A clear survivorship care plan that includes counseling on this "late effect" and a schedule for long-term cardiac surveillance should be established and communicated to the patient and their primary care providers.
  4. Leverage Advanced Formulations for Their Approved Indications: The liposomal formulation Vyxeos has demonstrated a clear survival advantage in its approved population (t-AML and AML-MRC) and should be considered the standard of care in that context. All clinicians, pharmacists, and nurses must be acutely aware of the FDA's "DO NOT INTERCHANGE" black box warning to prevent potentially fatal medication errors between Vyxeos and conventional daunorubicin/cytarabine preparations.

Future Directions:

Future research should prioritize two critical areas to further refine the use of daunorubicin:

  1. Validation of Cardiotoxicity Ratios: Large-scale, prospective, or well-designed real-world evidence studies are needed to definitively validate the relative cardiotoxicity of daunorubicin compared to doxorubicin. Confirming a ratio closer to 0.5:1, as suggested by retrospective data, could fundamentally alter cumulative dose calculations and long-term surveillance protocols, potentially making treatment safer for thousands of patients.
  2. Development of Predictive Biomarkers: While broad categories like age and cytogenetics guide dosing, the development and validation of more precise predictive biomarkers are needed. Identifying which patients are most likely to benefit from dose intensification versus those who are genetically predisposed to severe toxicity would represent the next step towards a truly personalized approach to anthracycline therapy, maximizing efficacy while minimizing harm.

Works cited

  1. Daunorubicin - Wikipedia, accessed July 21, 2025, https://en.wikipedia.org/wiki/Daunorubicin
  2. Daunorubicin - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK559073/
  3. Cerubidine (Daunorubicin): Side Effects, Uses, Dosage, Interactions ..., accessed July 21, 2025, https://www.rxlist.com/cerubidine-drug.htm
  4. What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/28154969/
  5. Benefit of high-dose daunorubicin in AML induction extends across ..., accessed July 21, 2025, https://ashpublications.org/blood/article/127/12/1551/35035/Benefit-of-high-dose-daunorubicin-in-AML-induction
  6. FDA Approves liposome-encapsulated combination of daunorubicin-cytarabine for adults with some types of poor prognosis AML - Florida Society of Clinical Oncology, accessed July 21, 2025, https://flasco.org/fda-approves-liposome-encapsulated-combination-daunorubicin-cytarabine-adults-types-poor-prognosis-aml/
  7. DRUG NAME: Daunorubicin - BC Cancer, accessed July 21, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Daunorubicin_monograph.pdf
  8. Daunorubicin - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 21, 2025, https://www.pediatriconcall.com/drugs/daunorubicin/466
  9. Daunorubicin (hydrochloride) (CAS 23541-50-6) - Cayman Chemical, accessed July 21, 2025, https://www.caymanchem.com/product/14159/daunorubicin-(hydrochloride)
  10. Daunorubicin | C27H29NO10 | CID 30323 - PubChem, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Daunorubicin
  11. DAUNORUBICIN | 20830-81-3 - Sigma-Aldrich, accessed July 21, 2025, https://www.sigmaaldrich.com/US/en/product/astatechinc/ate458963507?context=bbe
  12. Pfizer (Perth) Daunorubicin 2 mg/mL solution for injection. - Medsafe, accessed July 21, 2025, https://www.medsafe.govt.nz/profs/datasheet/d/daunorubicininj.pdf
  13. Daunorubicin | Leukemia and Lymphoma Society, accessed July 21, 2025, https://lls.org/drug/daunorubicin
  14. Anthracyclines (daunorubicin, doxorubicin, idarubicin and mitoxantrone) | Great Ormond Street Hospital, accessed July 21, 2025, https://www.gosh.nhs.uk/conditions-and-treatments/medicines-information/anthracyclines-daunorubicin-doxorubicin-idarubicin-and-mitoxantrone/
  15. DAUNOrubicin - Cancer Care Ontario, accessed July 21, 2025, https://www.cancercareontario.ca/en/system/files_force/daunorubicin.pdf?download=1
  16. Daunorubicin|DNA topoisomerase II inhibitor - APExBIO, accessed July 21, 2025, https://www.apexbt.com/daunorubicin.html
  17. Daunorubicin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00694
  18. DAUNOrubicin - Cancer Care Ontario, accessed July 21, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/43791
  19. Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group - PMC - PubMed Central, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4282931/
  20. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/27738808/
  21. Drug Shortage Detail: Daunorubicin Hydrochloride Injection - ASHP, accessed July 21, 2025, https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=2
  22. Daunorubicin Liposomal Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 21, 2025, https://www.drugs.com/dosage/daunorubicin-liposomal.html
  23. Search Orphan Drug Designations and Approvals - FDA, accessed July 21, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=73693
  24. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/30541745/
  25. (daunorubicin) dosing, indications, interactions, adverse effects, and ..., accessed July 21, 2025, https://reference.medscape.com/drug/daunorubicin-342118
  26. Daunorubicin Intravenous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed July 21, 2025, https://www.webmd.com/drugs/2/drug-5021/daunorubicin-intravenous/details
  27. Reference ID: 4134238 This label may not be the latest approved by FDA. For current labeling information, please visit https:// - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
  28. Vyxeos (cytarabine and daunorubicin) FDA Approval History - Drugs.com, accessed July 21, 2025, https://www.drugs.com/history/vyxeos.html
  29. Daunorubicin (intravenous route) - Side effects & dosage - Mayo Clinic, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/daunorubicin-intravenous-route/description/drg-20063348
  30. Daunorubicin Interactions Checker - Drugs.com, accessed July 21, 2025, https://www.drugs.com/drug-interactions/daunorubicin.html
  31. go.drugbank.com, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00694#:~:text=Carboplatin-,The%20risk%20or%20severity%20of%20adverse%20effects%20can%20be,Daunorubicin%20is%20combined%20with%20Carboplatin.&text=Carfilzomib-,The%20risk%20or%20severity%20of%20adverse%20effects%20can%20be,Daunorubicin%20is%20combined%20with%20Carfilzomib.&text=Carmustine-,The%20risk%20or%20severity%20of%20adverse%20effects%20can%20be,Carmustine%20is%20combined%20with%20Daunorubicin.
  32. Daunorubicin vs Doxorubicin Comparison - Drugs.com, accessed July 21, 2025, https://www.drugs.com/compare/daunorubicin-vs-doxorubicin
  33. Drug Interaction Report: daunorubicin liposomal, Probiotic Formula - Drugs.com, accessed July 21, 2025, https://www.drugs.com/interactions-check.php?drug_list=789-0,3205-15943&professional=1
  34. The anthracyclines: will we ever find a better doxorubicin? - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/1462166/
  35. Daunorubicin - brand name list from Drugs.com, accessed July 21, 2025, https://www.drugs.com/ingredient/daunorubicin.html
  36. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome - PubMed Central, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3142364/
  37. 07 Medicine of the week: Doxorubicin - YouTube, accessed July 21, 2025, https://www.youtube.com/watch?v=sI8wI6rn0HE
  38. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03 - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/22948968/
  39. EQUIVALENCE RATIO FOR DAUNORUBICIN TO DOXORUBICIN ..., accessed July 21, 2025, https://ccss.stjude.org/content/dam/en_US/shared/ccss/documents/abstract/abstract1522.pdf
  40. (PDF) Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysis - ResearchGate, accessed July 21, 2025, https://www.researchgate.net/publication/327166436_Efficacy_and_Toxicity_of_Idarubicin_Versus_High-dose_Daunorubicin_for_Induction_Chemotherapy_in_Adult_Acute_Myeloid_Leukemia_A_Systematic_Review_and_Meta-analysis
  41. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study - American Society of Hematology, accessed July 21, 2025, https://ashpublications.org/blood/article/117/8/2358/28389/Randomized-study-of-induction-therapy-comparing
  42. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience | Haematologica, accessed July 21, 2025, https://haematologica.org/article/view/10688
  43. Generic DAUNORUBICIN HYDROCHLORIDE INN entry, drug patent expiry and freedom to operate - DrugPatentWatch, accessed July 21, 2025, https://www.drugpatentwatch.com/p/generic/daunorubicin+hydrochloride
  44. FDA approves liposome-encapsulated combination of daunorubicin-cytarabine for adults with some types of poor prognosis AML, accessed July 21, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-liposome-encapsulated-combination-daunorubicin-cytarabine-adults-some-types-poor
  45. DAUNOrubicin (Conventional) | Drug Lookup | Pediatric Care Online ..., accessed July 21, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5265/DAUNOrubicin-Conventional
  46. Vyxeos patent expiration - Pharsight, accessed July 21, 2025, https://pharsight.greyb.com/drug/vyxeos-patent-expiration

Published at: July 21, 2025

This report is continuously updated as new research emerges.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.